Structure-based drug discovery using GPCR homology modeling: Successful virtual screening for antagonists of the alpha1A adrenergic receptor

Journal of Medicinal Chemistry

Volumn 48, Issue 4, 2005, Pages 1088-1097

  Evers, Andreas ^a   Klabunde, Thomas ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; G PROTEIN COUPLED RECEPTOR; RHODOPSIN;

ACCURACY; ARTICLE; BINDING AFFINITY; BINDING SITE; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SCREENING; MOLECULAR MODEL; PHARMACOPHORE; PROTEIN PROTEIN INTERACTION; SCORING SYSTEM; SEQUENCE ALIGNMENT; STRUCTURE ACTIVITY RELATION; VALIDATION PROCESS;

ADRENERGIC ALPHA-ANTAGONISTS; AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CATTLE; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NAPHTHOQUINONES; PIPERAZINES; PYRIDAZINES; PYRIDINES; RECEPTORS, ADRENERGIC, ALPHA-1; RHODOPSIN; SEQUENCE ALIGNMENT; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 13944255377     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0491804     Document Type: Article

References (73)

1. Klabunde, T.; Hessler, G. Drug design strategies for targeting G-protein-coupled receptors. Chembiochem. 2002, 3, 928-944.
2. Zhong, H.; Minneman, K. P. Alpha1-adrenoceptor subtypes. Eur. J. Pharmacol. 1999, 375, 261-276.
3. Flohr, S.; Kurz, M.; Kostenis, E.; Brkovich, A.; Fournier, A.; Klabunde, T. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. J. Med. Chem. 2002, 45, 1799-1805.
4. Marriott, D. P.; Dougall, I. G.; Meghani, P.; Liu, Y. J.; Flower, D. R. Lead generation using pharmacophore mapping and three-dimensional database searching: Application to muscarinic M(3) receptor antagonists. J. Med. Chem. 1999, 42, 3210-3216.
5. Becker, O. M.; Shacham, S.; Marantz, Y.; Noiman, S. Modeling the 3D structure of GPCRs: Advances and application to drug discovery. Curr. Opin. Drug Discovery Dev. 2003, 6, 353-361.
6. Becker, O. M.; Marantz, Y.; Shacham, S.; Inbal, B.; Heifetz, A.; Kalid, O.; Bar-Haim, S.; Warshaviak, D.; Fichman, M.; Noiman, S. G protein-coupled receptors: In silico drug discovery in 3D. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 11304-11309.
7. Bissantz, C.; Bernard, P.; Hibert, M.; Rognan, D. Protein-based virtual screening of chemical databases. II. Are homology models of G-Protein Coupled Receptors suitable targets? Proteins 2003, 50, 5-25.
8. Bissantz, C.; Logean, A.; Rognan, D. High-throughput modeling of human G-protein coupled receptors: Amino acid sequence alignment, three-dimensional model building, and receptor library screening. J. Chem. Inf. Comput. Sci. 2004, 44, 1162-1176.
9. Evers, A.; Klebe, G. Ligand-supported homology modeling of g-protein-coupled receptor sites: Models sufficient for successful virtual screening. Angew. Chem., Int. Ed. 2004, 43, 248-251.
10. Evers, A.; Klebe, G. Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. J. Med. Chem. 2004, 47, 5381-5392.
11. Varady, J.; Wu, X.; Fang, X.; Min, J.; Hu, Z.; Levant, B.; Wang, S. Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: Discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach. J. Med. Chem. 2003, 46, 4377-4392.
12. Broer, B. M.; Gurrath, M.; Holtje, H. D. Molecular modelling studies on the ORL1-receptor and ORL1-agonists. J. Comput. Aided Mol. Des. 2003, 17, 739-754.
13. Chambers, J. J.; Nichols, D. E. A homology-based model of the human 5-HT2A receptor derived from an in silico activated G-protein coupled receptor. J. Comput. Aided Mol. Des. 2002, 16, 511-520.
14. Freddolino, P. L.; Kalani, M. Y.; Vaidehi, N.; Floriano, W. B.; Hall, S. E.; Trabanino, R. J.; Kam, V. W.; Goddard, W. A., III Predicted 3D structure for the human beta 2 adrenergic receptor and its binding site for agonists and antagonists. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 2736-2741.
15. Furse, K. E.; Lybrand, T. P. Three-dimensional models for beta-adrenergic receptor complexes with agonists and antagonists. J. Med. Chem. 2003, 46, 4450-4462.
16. Johren, K.; Holtje, H. D. A model of the human M2 muscarinic acetylcholine receptor. J. Comput. Aided Mol. Des. 2002, 16, 795-801.
17. Kalani, M. Y.; Vaidehi, N.; Hall, S. E.; Trabanino, R. J.; Freddolino, P. L.; Kalani, M. A.; Floriano, W. B.; Kam, V. W.; Goddard, W. A., III The predicted 3D structure of the human D2 dopamine receptor and the binding site and binding affinities for agonists and antagonists. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 3815-3820.
18. Lavecchia, A.; Greco, G.; Novellino, E.; Vittorio, F.; Ronsisvalle, G. Modeling of kappa-opioid receptor/agonists interactions using pharmacophore-based and docking simulations. J. Med. Chem. 2000, 43, 2124-2134.
19. Onuffer, J.; McCarrick, M. A.; Dunning, L.; Liang, M.; Rosser, M.; Wei, G. P.; Ng, H.; Horuk, R. Structure function differences in nonpeptide CCR1 antagonists for human and mouse CCR1. J. Immunol. 2003, 170, 1910-1916.
20. Pedretti, A.; Elena, S. M.; Villa, L.; Vistoli, G. Binding site analysis of full-length alpha1a adrenergic receptor using homology modeling and molecular docking. Biochem. Biophys. Res. Commun. 2004, 319, 493-500.
21. Salo, O. M.; Lahtela-Kakkonen, M.; Gynther, J.; Jarvinen, T.; Poso, A. Development of a 3D model for the human cannabinoid CB1 receptor. J. Med. Chem. 2004, 47, 3048-3057.
22. Shim, J. Y.; Welsh, W. J.; Howlett, A. C. Homology model of the CB1 cannabinoid receptor: Sites critical for nonclassical cannabinoid agonist interaction. Biopolymers 2003, 71, 169-189.
23. Evers, A.; Gohlke, H.; Klebe, G. Ligand-supported homology modelling of protein binding-sites using knowledge-based potentials. J. Mol. Biol. 2003, 334, 327-345.
24. Baker, D.; Sali, A. Protein structure prediction and structural genomics. Science 2001, 294, 93-96.
25. Hillisch, A.; Pineda, L. F.; Hilgenfeld, R. Utility of homology models in the drug discovery process. Drug Discovery Today 2004, 9, 659-669.
26. Zhao, M. M.; Hwa, J.; Perez, D. M. Identification of critical extracellular loop residues involved in alpha 1-adrenergic receptor subtype-selective antagonist binding. Mol. Pharmacol. 1996, 50, 1118-1126.
27. Shi, L.; Javitch, J. A. The binding site of aminergic G protein-coupled receptors: The transmembrane segments and second extracellular loop. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 437-467.
28. Hwa, J.; Perez, D. M. The unique nature of the serine interactions for alpha 1-adrenergic receptor agonist binding and activation. J. Biol. Chem. 1996, 271, 6322-6327.
29. Hwa, J.; Graham, R. M.; Perez, D. M. Identification of critical determinants of alpha 1-adrenergic receptor subtype selective agonist binding. J. Biol. Chem. 1995, 270, 23189-23195.
30. Hamaguchi, N.; True, T. A.; Saussy, D. L., Jr.; Jeffs, P. W. Phenylalanine in the second membrane-spanning domain of alpha 1A-adrenergic receptor determines subtype selectivity of dihydropyridine antagonists. Biochemistry 1996, 35, 14312-14317.
31. Hamaguchi, N.; True, T. A.; Goetz, A. S.; Stouffer, M. J.; Lybrand, T. P.; Jeffs, P. W. Alpha 1-adrenergic receptor subtype determinants for 4-piperidyl oxazole antagonists. Biochemistry 1998, 37, 5730-5737.
32. Waugh, D. J.; Gaivin, R. J.; Zuscik, M. J.; Gonzalez-Cabrera, P.; Ross, S. A.; Yun, J.; Perez, D. M. Phe-308 and Phe-312 in transmembrane domain 7 are major sites of alpha 1-adrenergic receptor antagonist binding. Imidazoline agonists bind like antagonists. J. Biol. Chem. 2001, 276, 25366-25371.
33. Waugh, D. J.; Zhao, M. M.; Zuscik, M. J.; Perez, D. M. Novel aromatic residues in transmembrane domains IV and V involved in agonist binding at alpha(1a)-adrenergic receptors. J. Biol. Chem. 2000, 275, 11698-11705.
34. Almaula, N.; Ebersole, B. J.; Zhang, D.; Weinstein, H.; Sealfon, S. C. Mapping the binding site pocket of the serotonin 5-Hydroxy-tryptamine2A receptor. Ser3.36(159) provides a second interaction site for the protonated amine of serotonin but not of lysergic acid diethylamide orbufotenin. J. Biol. Chem. 1996, 271, 14672-14675.
35. Boess, F. G.; Monsma, F. J., Jr.; Sleight, A. J. Identification of residues in transmembrane regions III and VI that contribute to the ligand binding site of the serotonin 5-HT6 receptor. J. Neurochem. 1998, 71, 2169-2177.
36. Chen, S.; Xu, M.; Lin, F.; Lee, D.; Riek, P.; Graham, R. M. Phe310 in transmembrane VI of the alpha1B-adrenergic receptor is a key switch residue involved in activation and catecholamine ring aromatic bonding. J. Biol. Chem. 1999, 274, 16320-16330.
37. Fraser, C. M.; Wang, C. D.; Robinson, D. A.; Gocayne, J. D.; Venter, J. C. Site-directed mutagenesis of m1 muscarinic acetylcholine receptors: Conserved aspartic acids play important roles in receptor function. Mol. Pharmacol. 1989, 36, 840-847.
38. Fu, D.; Ballesteros, J. A.; Weinstein, H.; Chen, J.; Javitch, J. A. Residues in the seventh membrane-spanning segment of the dopamine D2 receptor accessible in the binding-site crevice. Biochemistry 1996, 35, 11278-11285.
39. Javitch, J. A.; Li, X.; Kaback, J.; Karlin, A. A cysteine residue in the third membrane-spanning segment of the human D2 dopamine receptor is exposed in the binding-site crevice. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 10355-10359.
40. Javitch, J. A.; Fu, D.; Chen, J. Residues in the fifth membrane-spanning segment of the dopamine D2 receptor exposed in the binding-site crevice. Biochemistry 1995, 34, 16433-16439.
41. Javitch, J. A.; Ballesteros, J. A.; Weinstein, H.; Chen, J. A cluster of aromatic residues in the sixth membrane-spanning segment of the dopamine D2 receptor is accessible in the binding-site crevice. Biochemistry 1998, 37, 998-1006.
42. Javitch, J. A.; Ballesteros, J. A.; Chen, J.; Chiappa, V.; Simpson, M. M. Electrostatic and aromatic microdomains within the binding-site crevice of the D2 receptor: Contributions of the second membrane-spanning segment. Biochemistry 1999, 38, 7961-7968.
43. Javitch, J. A.; Shi, L.; Simpson, M. M.; Chen, J.; Chiappa, V.; Visiers, I.; Weinstein, H.; Ballesteros, J. A. The fourth transmembrane segment of the dopamine D2 receptor: Accessibility in the binding-site crevice and position in the transmembrane bundle. Biochemistry 2000, 39, 12190-12199.
44. Kao, H. T.; Adham, N.; Olsen, M. A.; Weinshank, R. L.; Branchek, T. A.; Hartig, P. R. Site-directed mutagenesis of a single residue changes the binding properties of the serotonin 5-HT2 receptor from a human to a rat pharmacology. FEBS Lett. 1992, 307, 324-328.
45. Roth, B. L.; Shoham, M.; Choudhary, M. S.; Khan, N. Identification of conserved aromatic residues essential for agonist binding and second messenger production at 5-hydroxytryptamine2A receptors. Mol. Pharmacol. 1997, 52, 259-266.
46. Roth, B. L.; Willins, D. L.; Kristiansen, K.; Kroeze, W. K. 5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamme2C): Where structure meets function. Pharmacol. Ther. 1998, 79, 231-257.
47. Shi, L.; Javitch, J. A. The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 440-445.
48. Simpson, M. M.; Ballesteros, J. A.; Chiappa, V.; Chen, J.; Suehiro, M.; Hartman, D. S.; Godel, T.; Snyder, L. A.; Sakmar, T. P.; Javitch, J. A. Dopamine D4/D2 receptor selectivity is determined by A divergent aromatic microdomain contained within the second, third, and seventh membrane-spanning segments. Mol. Pharmacol. 1999, 56, 1116-1126.
49. Ballesteros, J. A.; Weinstein, H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci. 1996, 25, 366-428.
50. Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. Improved protein-ligand docking using GOLD. Proteins 2003, 52, 609-623.
51. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
52. Jones, G.; Willett, P.; Glen, R. C. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J. Mol. Biol. 1995, 245, 43-53.
53. Gohlke, H.; Hendlich, M.; Klebe, G. Knowledge-based scoring function to predict protein-ligand interactions. J. Mol. Biol. 2000, 295, 337-356.
54. Halgren, T. A. Merck molecular force field. I. Basis, form, scope, parametrization, and performance of MMFF94. J. Comput. Chem. 1996, 7, 490-641.
55. Klabunde, T.; Evers, A. accepted at Chembiochem.
56. Wang, R.; Lu, Y.; Wang, S. Comparative evaluation of 11 scoring functions for molecular docking. J. Med. Chem. 2003, 46, 2287-2303.
57. Wang, R.; Lai, L.; Wang, S. Further development and validation of empirical scoring functions for structure-based binding affinity prediction. J. Comput. Aided Mol. Des. 2002, 16, 11-26.
58. Kuntz, I. D.; Blaney, J. M.; Oatley, S. J.; Langridge, R.; Ferrin, T. E. A geometric approach to macromolecule-ligand interactions. J. Mol. Biol. 1982, 161, 269-288.
59. Eldridge, M. D.; Murray, C. W.; Auton, T. R.; Paolini, G. V.; Mee, R. P. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J. Comput. Aided Mol. Des. 1997, 11, 425-445.
60. Muegge, I.; Martin, Y. C. A general and fast scoring function for protein-ligand interactions: A simplified potential approach. J. Med. Chem. 1999, 42, 791-804.
61. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 1996, 261, 470-489.
62. Brenk, R.; Naerum, L.; Gradler, U.; Gerber, H. D.; Garcia, G. A.; Reuter, K.; Stubbs, M. T.; Klebe, G. Virtual screening for submicromolar leads of tRNA-guanine transglycosylase based on a new unexpected binding mode detected by crystal structure analysis. J. Med. Chem. 2003, 46, 1133-1143.
63. Gruneberg, S.; Stubbs, M. T.; Klebe, G. Successful virtual screening for novel inhibitors of human carbonic anhydrase: Strategy and experimental confirmation. J. Med. Chem. 2002, 45, 3588-3602.
64. Hendrix, J. A.; Strupczewski, J. T.; Bordeau, K. J.; Urmann, M.; Shutske, G.; Hemmerle, H.; Jurcak, J. G.; Gill, H.; Weiberth, F.; Nieduzak, T.; Jackson, S. A.; Zhao, X.-Y.; Mueller, P. J. Preparation of heterocyclic amides as dopamine D3 receptors for treating central nervous system disorders. PCT Int. Appl. WO 2002-US4917[WO 2002066469]. 4-10-2002.
65. Oliveira, L.; Hulsen, T.; Lutje, H. D.; Paiva, A. C.; Vriend, G. Heavier-than-air flying machines are impossible. FEBS Lett. 2004, 564, 269-273.
66. Oliveira, L.; Paiva, A. C.; Vriend, G. Correlated mutation analyses on very large sequence families. Chembiochem 2002, 3, 1010-1017.
67. Kim, J.; Jiang, Q.; Glashofer, M.; Yehle, S.; Wess, J.; Jacobson, K. A. Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition. Mol. Pharmacol. 1996, 49, 683-691.
68. Hiramoto, T.; Nonaka, Y.; Inoue, K.; Yamamoto, T.; Omatsu-Kanbe, M.; Matsuura, H.; Gohda, K.; Fujita, N. Identification of endogenous surrogate ligands for human P2Y receptors through an in silico search. J. Pharmacol. Sci. 2004, 95, 81-93.
69. Ferrara, P.; Gohlke, H.; Price, D. J.; Klebe, G.; Brooks, C. L., III Assessing scoring functions for protein-ligand interactions. J. Med. Chem. 2004, 47, 3032-3047.
70. Jalaie, M.; Erickson, J. A. Homology model directed alignment selection for comparative molecular field analysis: Application to photosystem II inhibitors. J. Comput. Aided Mol. Des. 2000, 14, 181-197.
71. Schafferhans, A.; Klebe, G. Docking ligands onto binding site representations derived from proteins built by homology modelling. J. Mol. Biol. 2001, 307, 407-427.
72. Peroutka, S. J.; U'Prichard, D. C.; Greenberg, D. A.; Snyder, S. H. Neuroleptic drug interactions with norepinephrine alpha receptor binding sites in rat brain. Neuropharmacology 1977, 16, 549-556.
73. Michel, A. D.; Loury, D. N.; Whiting, R. L. Identification of a single alpha 1-adrenoceptor corresponding to the alpha 1A-subtype in rat submaxillary gland. Br. J. Pharmacol. 1989, 98, 883-889.